A Study Comparing Pharmacokinetic and Safety of QL2107 and Keytruda® (Marketed in China and the United States) in Healthy Adults

Tumor Clinical Trial

Official title:

A Randomized, Double-blind, Single-dose, Parallel Three-group Study to Compare the Pharmacokinetics and Safety of QL2107 and Keytruda® (Marketed in China and the United States) in Healthy Male Adults

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06173011
• Other study ID #: QL2107-101
• Status: Recruiting
• Phase: Phase 1
• Start date: December 12, 2023
• Est. completion date: July 2024

Study information

• Verified date: November 2023
• Source: Qilu Pharmaceutical Co., Ltd.
• Contact: yanhua ding
• Phone: 0431-88782168
• Email: dingyanhua2003[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to compare the pharmacokinetic and safety similarity of QL2107 with Keytruda® marketed in China and the United States in healthy male volunteers. Participants will receive a single injection of QL2107/ Keytruda® （China）/Keytruda® （US）.Researchers will compare pharmacokinetic, safety, and immunogenic similarities between the three groups.

Description:

This is a phase I,single center, randomized, double-blind and parallel group clinical trial . The primary objective is to assess the pharmacokinetic similarity of single injections of QL2107 or Keytruda® （China/US） in healthy volunteers. The secondary objective are to assess the clinical safety and immunogenicity similarity of single injections of QL2107 or Keytruda® （China/US） in healthy volunteers. Subjects would receive a single 100mg（4ml） of QL2107or Keytruda® （China/US）injection.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 168
• Est. completion date: July 2024
• Est. primary completion date: July 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

1. Sign the informed consent form and fully understand the test content, process and possible adverse reactions, and be able to complete the study according to the test plan requirements;

2. Age 18 ~ 50 (inclusive) years , male;

3. 50.0 kg= body weight =90.0 kg and 18.0 kg/m2= Body mass index (BMI) =28.0 kg/m2;

4. Agree to use effective contraception throughout the study period (including but not limited to: physical contraception, surgery, abstinence, etc.) until at least 6 months after the study dosing;

5. No history of disease or abnormal past medical history is not clinically significant, and the study doctor's judgment has no impact on the trial. Exclusion criteria

Exclusion Criteria:

1. Clinical laboratory examination, infectious disease screening, chest orthogram examination, abdominal color ultrasound examination, 12-lead electrocardiogram, heart color ultrasound, physical examination, vital signs (systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg) the abnormalities in each examination have clinical significance or are determined to have an impact on the trial (subject to the judgment of the clinical study physician); (2) Have been or are currently suffering from any clinically serious disease of the circulatory system, endocrine system, nervous system, digestive system, respiratory system, urogenital system, hematology, immunology, psychiatric and metabolic abnormalities, or any other disease that can interfere with the test results;

3. Presence of any active autoimmune disease or history of autoimmune disease (including but not limited to: rheumatoid arthritis, ankylosing spondylitis, autoimmune hemolytic anemia, interstitial pneumonia, uveitis, inflammatory bowel disease, autoimmune hepatitis, autoimmune pituitaritis, glomerulonephritis, hyperthyroidism or hypothyroidism, etc.)

4. Known history of tuberculosis or suspected clinical manifestations of tuberculosis (including but not limited to tuberculosis, lymphatic tuberculosis, tuberculous pleurisy, etc.);

5. Patients with a history of acute infection within 2 weeks before screening;

6. There have been herpes zoster virus infections within 3 months before screening;

7. Viral hepatitis (including hepatitis B and C), AIDS antibody, treponema pallidum antibody screening positive;

8. Allergies (multiple drug and food allergies), who were determined by the researcher to be unable to participate in this study;

9. Patients who had surgery within 4 weeks prior to screening or planned to have surgery during the study period;

10. Those who have used any biological product or received live viral vaccine (tetanus toxoid vaccine within 1 year before infusion), used any monoclonal antibody within 6 months or 5 biological half-lives of drug metabolism, or used PD-1/PD-L1 drugs in the past;

11. Those who have used any drug or health product (including Chinese herbal medicine) within 14 days prior to the infusion of the experimental drug;

12. Participants who participated in any clinical trial and used any clinical trial drug within 3 months prior to screening;

13. Study patients who donated blood or lost a large amount of blood (> 400 mL) or received blood transfusions or used blood products within 3 months prior to administration;

14. Smokers or smokers who smoked more than 5 cigarettes per day in the 3 months prior to screening or who could not stop using any tobacco products during the trial;

15. Positive drug screening or/and alcohol breath test screening prior to study administration;

16. A history of drug and/or alcohol abuse (14 units of alcohol consumed per week "1 unit = 285 mL for beer, 25 mL for spirits, or 100 mL for wine");

17. Subjects who have other factors deemed unsuitable for the study by the investigator;

Related Conditions & MeSH terms

• Tumor

Intervention

Drug:
• QL2107
intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)
• Keytruda®(china)
intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)
• Keytruda®(US)
intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Jilin University	Changchun	Jilin

Sponsors (1)

Lead Sponsor	Collaborator
Qilu Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AUC0-8	To evaluate pharmacokinetic similarity between QL2107 and Keytruda® (china/US)after a single intravenous infusion in healthy volunteers	113day
Secondary	safety and immunogenicity	Safety, as defined by the rate of treatment-related adverse events as assessed by NCI CTCAE v5.0.after a single intravenous infusion in healthy volunteers;Immunogenicity will be assessed by the incidence of ADA and Nab.	113day
Secondary	Cmax	To evaluate pharmacokinetic similarity between QL2107 and Keytruda®	113day
Secondary	Tmax	To evaluate pharmacokinetic similarity between QL2107 and Keytruda®	113day
Secondary	AUC0-t	To evaluate pharmacokinetic similarity between QL2107 and Keytruda®	113day
Secondary	t1/2	To evaluate pharmacokinetic similarity between QL2107 and Keytruda®	113day
Secondary	CL	To evaluate pharmacokinetic similarity between QL2107 and Keytruda®	113day
Secondary	Vd	To evaluate pharmacokinetic similarity between QL2107 and Keytruda®	113day
Secondary	AUC_%Extrap	To evaluate pharmacokinetic similarity between QL2107 and Keytruda®	113day